Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics
COLL Price/Volume Stats
Current price | $35.42 | 52-week high | $40.95 |
Prev. close | $35.48 | 52-week low | $20.83 |
Day low | $35.05 | Volume | 2,825 |
Day high | $35.42 | Avg. volume | 425,503 |
50-day MA | $36.96 | Dividend yield | N/A |
200-day MA | $28.61 | Market Cap | 1.16B |
COLL Stock Price Chart Interactive Chart >
Collegium Pharmaceutical, Inc. (COLL) Company Bio
Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.
Latest COLL News From Around the Web
Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.
Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells Company SharesOn December 21, 2023, Joseph Ciaffoni, President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), executed a sale of 4,357 shares of the company. |
Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells 68,768 SharesJoseph Ciaffoni, the President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), sold 68,768 shares of the company on December 20, 2023, according to a recent SEC filing. |
Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up... |
Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock. |
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 PatentSTOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b |
COLL Price Returns
1-mo | -11.29% |
3-mo | 6.75% |
6-mo | 67.39% |
1-year | 55.08% |
3-year | 52.34% |
5-year | 136.29% |
YTD | 15.07% |
2023 | 32.67% |
2022 | 24.20% |
2021 | -6.74% |
2020 | -2.67% |
2019 | 19.86% |
Continue Researching COLL
Here are a few links from around the web to help you further your research on Collegium Pharmaceutical Inc's stock as an investment opportunity:Collegium Pharmaceutical Inc (COLL) Stock Price | Nasdaq
Collegium Pharmaceutical Inc (COLL) Stock Quote, History and News - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...